Can Bimekizumab Match IL-23 Inhibitors in Psoriasis?

Published Date: 26 Jun 2026

A retrospective study finds that bimekizumab yields comparable drug survival to interleukin-23 inhibitors after the failure of interleukin-17 inhibitors in patients with psoriasis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mental health risk persists years after cancer diagnosis

2.

Breast cancer prevention: How nurse practitioners and physician assistants can help

3.

For treatment, the majority of cancer patients choose complementary therapies.

4.

Cancer mortality continuing to decline, says report

5.

Doctors say lung cancer is still the deadliest cancer, but hope is growing


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot